KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Arbutus Biopharma (ABUS) over the last 13 years, with Q3 2025 value amounting to -$120000.0.

  • Arbutus Biopharma's Change in Receivables rose 2452.83% to -$120000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$703000.0, marking a year-over-year decrease of 2486.68%. This contributed to the annual value of $633000.0 for FY2024, which is 4929.25% up from last year.
  • Per Arbutus Biopharma's latest filing, its Change in Receivables stood at -$120000.0 for Q3 2025, which was up 2452.83% from -$157000.0 recorded in Q2 2025.
  • Arbutus Biopharma's 5-year Change in Receivables high stood at $1.3 million for Q1 2023, and its period low was -$1.2 million during Q1 2025.
  • Its 5-year average for Change in Receivables is -$21421.1, with a median of -$120000.0 in 2025.
  • Its Change in Receivables has fluctuated over the past 5 years, first soared by 189090.91% in 2022, then plummeted by 64400.0% in 2024.
  • Quarter analysis of 5 years shows Arbutus Biopharma's Change in Receivables stood at -$768000.0 in 2021, then skyrocketed by 37.11% to -$483000.0 in 2022, then grew by 18.22% to -$395000.0 in 2023, then soared by 302.78% to $801000.0 in 2024, then plummeted by 114.98% to -$120000.0 in 2025.
  • Its Change in Receivables was -$120000.0 in Q3 2025, compared to -$157000.0 in Q2 2025 and -$1.2 million in Q1 2025.